Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L3KA
|
|||
| Former ID |
DNCL002379
|
|||
| Drug Name |
BP-100-1-01
|
|||
| Indication | Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7] | Phase 2 | [1] | |
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 2 | [1] | ||
| Chronic myelogenous leukaemia [ICD-11: 2A20.0; ICD-10: C92.1] | Phase 2 | [1] | ||
| Hematologic tumour [ICD-11: 2B33.Y] | Phase 2 | [1] | ||
| Myelodysplastic syndrome [ICD-11: 2A37] | Phase 2 | [1] | ||
| Company |
Bio-Path Ogden, Utah
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032443) | |||
| REF 2 | ClinicalTrials.gov (NCT01159028) Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS. U.S. National Institutes of Health. | |||
| REF 3 | Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01. Expert Opin Drug Deliv. 2015 Jul;12(7):1107-20. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.